Blood pressure control in patients receiving bevacizumab in an outpatient cancer center

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 4, 2011, Pages 333-338

  Bottiglieri, Sal ^a   Muluneh, Benyam ^b   Sutphin, Stephanie ^a,c   Iacovelli, Lew ^b   Adams, Val ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MOSES CONE HEALTH SYSTEM   (United States)

^c University of Kentucky   (United States)

Author keywords

angiogenesis; Bevacizumab; blood pressure; hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; BLOOD PRESSURE REGULATION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES;

EID: 82555176756     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210382150     Document Type: Review

References (17)

1. Genentech I. Bevacizumab Package Insert, 2009.
2. Scolnik P.. mAbs, A business perspective. mAbs. 2009 ; 1 (2). 179-184
3. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A.. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009 ; 66 (11). 999-1013
4. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 ; 349 (5). 427-434 (Pubitemid 36910021)
5. Gressett SM, Shah SR.. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009 ; 43 (3). 490-501
6. Pouessel D, Culine S.. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008 ; 53 (2). 376-381 (Pubitemid 350296582)
7. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009 ; 20 (5). 807-815
8. Gurevich F, Perazella MA.. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009 ; 122 (4). 322-328
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 ; 350 (23). 2335-2342 (Pubitemid 38702844)
10. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003 ; 289 (19). 2560-2572 (Pubitemid 37430158)
11. Pool JL, Kaihlanen P, Lewis GR, Oparil S, Glazer R, Messerli FH.. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hyperten. 2001 ; 15: 495-498 (Pubitemid 32640266)
12. Philipp T, Smith SR, Glazer R, Wernsing M, Yen J, Jin J.. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Therap. 2007 ; 29 (4). 563-580 (Pubitemid 47028551)
13. Gomez HJ, Cirillo VJ, Sromovsky JA, Otterbein WC, Shaw WC, Rush JE.. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmac. 1989 ; 28: 415-420 (Pubitemid 19269779)
14. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K.. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase ii randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol. 2009 ; 27 (36). 6152-6159
15. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K.. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes enodthelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res. 2005 ; 28 (2). 147-153 (Pubitemid 40663066)
16. Siddiqui AJ, Mansson-Broberg A, Gustafsson T, Grinnemo KH, Dellgreen G, Hao X.. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens. 2005 ; 18 (10). 1347-1352 (Pubitemid 41400206)
17. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M.. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 2006 ; 12 (9). 2888-2893